Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Targets |
TGFβRII; p38 MAPK (IC50 = 20 nM)
|
---|---|
ln Vitro |
TA-02 (5 μM) inhibits the phosphorylation of MAPKAPK2 and HSP27, proteins that are phosphorylated by the p38α MAPK during cardiogenesis. Contrary to what would be predicted by a mechanism dependent on p38α MAPK inhibition, TA-02 at a concentration of 5 μM induces cardiogenesis while also increasing ATF-2 phosphorylation and MEF2C õexpression[1].
TA-02 induces T/Brachyury, whereas SB203580 addition increased MESP1 and T/Brachyury transcripts[1]. TA-02 significantly raises NKX2-5 expression when applied between days 0 and 8[1]. TA-02 is discovered to inhibit numerous targets with similar potency to p38α MAPK, including p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2[1]. Nuclear TCF/LEF-1 driven transcription of the DKK-1-like luciferase is inhibited by TA-02 and SB203580[1]. In vitro, TA-02 (5 nM–5 M) increases BDNF's anti-inflammation effects while inhibiting p38[2]. |
References |
Molecular Formula |
C20H13F2N3
|
---|---|
Molecular Weight |
333.3341
|
Exact Mass |
333.11
|
Elemental Analysis |
C, 72.06; H, 3.93; F, 11.40; N, 12.61
|
CAS # |
1784751-19-4
|
Related CAS # |
TA-01;1784751-18-3
|
Appearance |
White to off-white solid powder
|
SMILES |
C1=CC=C(C(=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)F
|
InChi Key |
QIFJOFNVIVQRNJ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C20H13F2N3/c21-15-7-5-13(6-8-15)18-19(14-9-11-23-12-10-14)25-20(24-18)16-3-1-2-4-17(16)22/h1-12H,(H,24,25)
|
Chemical Name |
4-[2-(2-fluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyridine
|
Synonyms |
TA 02; TA02; TA-02
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 25~67 mg/mL (75.0~201.0 mM)
Ethanol: ~3 mg/mL (~9.0 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0000 mL | 15.0002 mL | 30.0003 mL | |
5 mM | 0.6000 mL | 3.0000 mL | 6.0001 mL | |
10 mM | 0.3000 mL | 1.5000 mL | 3.0000 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.